|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-2-27
|
|
pubmed:abstractText |
Vesicular stomatitis virus (VSV) is a negative-strand ribonucleic acid (RNA) virus that replicates specifically in tumor cells and has oncolytic effects in a variety of malignant tumors. We previously demonstrated recombinant VSV vectors incorporating viral fusion protein (rVSV-F) and interleukin 12 (rVSV-IL12) to have significant antitumor effects against squamous cell carcinoma (SCC) in a murine model. Here we evaluate the potential to combine a potent chemotherapeutic agent for SCC (cisplatin) with rVSV-F and rVSV-IL12 to improve efficacy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/G protein, vesicular stomatitis...,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-12,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Envelope Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Fusion Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0023-852X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
118
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
237-42
|
|
pubmed:meshHeading |
pubmed-meshheading:18043494-Animals,
pubmed-meshheading:18043494-Antineoplastic Agents,
pubmed-meshheading:18043494-Carcinoma, Squamous Cell,
pubmed-meshheading:18043494-Cell Line, Tumor,
pubmed-meshheading:18043494-Cisplatin,
pubmed-meshheading:18043494-Combined Modality Therapy,
pubmed-meshheading:18043494-Disease Models, Animal,
pubmed-meshheading:18043494-Female,
pubmed-meshheading:18043494-Head and Neck Neoplasms,
pubmed-meshheading:18043494-Interleukin-12,
pubmed-meshheading:18043494-Membrane Glycoproteins,
pubmed-meshheading:18043494-Mice,
pubmed-meshheading:18043494-Mice, Inbred C3H,
pubmed-meshheading:18043494-Mouth Floor,
pubmed-meshheading:18043494-Oncolytic Virotherapy,
pubmed-meshheading:18043494-Polymerase Chain Reaction,
pubmed-meshheading:18043494-RNA, Viral,
pubmed-meshheading:18043494-Recombinant Fusion Proteins,
pubmed-meshheading:18043494-Survival Rate,
pubmed-meshheading:18043494-Vesiculovirus,
pubmed-meshheading:18043494-Viral Envelope Proteins,
pubmed-meshheading:18043494-Viral Fusion Proteins
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
|
|
pubmed:affiliation |
Department of Otolaryngology-Head and Neck Surgery, Mount Sinai School of Medicine, New York, New York 10029, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
